The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

Blood

Volumn 90, Issue 9, 1997, Pages 3691-3698

  Deininger, Michael W N ^b   Goldman, John M ^b   Lydon, Nicholas ^b   Melo, Junia V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; DNA FRAGMENT; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BURST FORMING UNIT E; CELL PROLIFERATION; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

EID: 0030853063     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3691     Document Type: Article

References (32)

1. Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM: Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75:464, 1995
2. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON: Expression of a distinctive BCR-ABL oncogene in Phi-positive acute lymphocytic leukemia (ALL). Science 239:775, 1988
3. Melo JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375, 1996
4. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B: Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88:2410, 1996
5. Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-ab1 protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035, 1984
6. Spencer A, O'Brien SG, Goldman JM: Options for therapy in chronic myeloid leukaemia. Br J Haematol 91:2, 1995
7. Italian Cooperative Study Group on CML: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 330:820, 1994
8. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges F-J, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, v. Wussow P, Prümmer O, Thiele J, Buhr F, Carbonell F, Ansari H, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84:4064, 1994
9. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079, 1990
10. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA: Tyrphostin induced growth inhibition: Correlation with effect on p210bcr-ab1 autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 5:213, 1994
11. Anafi M, Gazit A, Zehavi A, Ben Neriah Y, Levitzki A: Tyrphostin-induced inhibition of p210bcr-ab1 tyrosine kinase activity induces K562 to differentiate. Blood 82:3524, 1993
12. Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni Eda Y, Kurosawa M, Miyazaki T: Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/ab1 oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/ab1 and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80:1330, 1992
13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB: Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat Med 2:561, 1996
14. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM: Inhibition of acute lymphoblastic leukaemia by a Jak2 inhibitor. Nature 379:645, 1996
15. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 267:1782, 1995
16. Buchdunger E, Zimmerman J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Ab1 protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100, 1996
17. Diamond J, Goldman JM, Melo JV: BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocytemacrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 85:2171, 1995
18. Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martial P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse. Br J Haematol 84:67, 1993
19. Cross NC, Lin F, Goldman JM: Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR). Br J Haematol 87:218, 1994
20. Ono K, Alter BP: Effects of low oxygen tension and amioxidants on human erythropoiesis in vitro. Exp Hemutol 23:1372, 1995
21. Maeda H, Hotta T, Yamada H: Enhanced colony formation of human hemopoietic stem cells in reduced oxygen tension. Exp Hematol 14:930, 1986
22. Lumley MA, Burgess R, Billingham LJ, McDonald DF, Miligan DW: Colony counting is a major source of variation on CPUCM results between centres. Br J Haematol 93:49, 1996
23. + cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 83:1744, 1994
24. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC: Characterization of primitive subpopulation of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162, 1996
25. Melo JV, Van XH, Diamond J, Lin F, Cross NC, Goldman JM: Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: The risk in misinterpreting negative results. Leukemia 10:1217, 1996
26. Thijsen SFT, Schuurhuis GJ, van Oostveen JW, Theijsmeijer AP, Langenhuijsen MMAC, Ossenkoppele GJ: Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: Interphase fluorescence in situ hybridization compared with RT-PCR. Leukemia 11:301, 1996
27. Melo JV, Gordon DE, Cross NC, Goldman JM: The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158, 1993
28. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O: The nuclear tyrosine kinase c-Ab1 negatively regulates cell growth, Cell 77:121, 1994
29. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
30. Evans CA, Owen Lynch PJ, Whetton AD, Dive C: Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53:1735, 1993
31. Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574, 1996
32. Kim IK, Lee JH, Sohn HW, Kim HS, Kim SH: Prostaglandin A2 and delta 12-prostaglandin J2 induce apoptosis in L1210 cells. FEBS Lett 321:209, 1993